Mutational activation of the ras gene is critical for the onset of different malignant phenotypes. We constructed a dominant negative mutant (GEF-DN) of a Ras activator protein (guanine nucleotide-exchange factor) that upon over-expression in k-ras transformed NIH 3T3 fibroblasts strongly reduces intracellular RaseGTP, reverting these cells to wild-type phenotype for morphology, anchorage-independent growth and reduction of tumour formation in nude mice. Here we review evidence showing that the enhanced proliferation potential of NIH-ras cells requires high initial glucose concentration in the medium and sustained Ras pathway activation. The exquisite sensitivity of NIH-ras fibroblasts to a shortage in nutrient and energy supply highlights an acquired fragility of cancer cells that may be exploited for therapeutic purposes. © 2005 Biochemical Society.
Chiaradonna, F., Magnani, C., Sacco, E., Manzoni, R., Alberghina, L., Vanoni, M. (2005). Acquired glucose sensitivity of k-ras transformed fibroblasts. BIOCHEMICAL SOCIETY TRANSACTIONS, 33(1), 297-299 [10.1042/BST0330297].
Acquired glucose sensitivity of k-ras transformed fibroblasts
CHIARADONNA, FERDINANDO;MAGNANI, CHIARA FRANCESCA;SACCO, ELENA;ALBERGHINA, LILIA;VANONI, MARCO ERCOLE
2005
Abstract
Mutational activation of the ras gene is critical for the onset of different malignant phenotypes. We constructed a dominant negative mutant (GEF-DN) of a Ras activator protein (guanine nucleotide-exchange factor) that upon over-expression in k-ras transformed NIH 3T3 fibroblasts strongly reduces intracellular RaseGTP, reverting these cells to wild-type phenotype for morphology, anchorage-independent growth and reduction of tumour formation in nude mice. Here we review evidence showing that the enhanced proliferation potential of NIH-ras cells requires high initial glucose concentration in the medium and sustained Ras pathway activation. The exquisite sensitivity of NIH-ras fibroblasts to a shortage in nutrient and energy supply highlights an acquired fragility of cancer cells that may be exploited for therapeutic purposes. © 2005 Biochemical Society.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.